Cotinga Pharmaceuticals

Cotinga Pharmaceuticals developed a pipeline of targeted small molecule therapies against key oncogenic drivers such as mutant p53 and KRAS. Their lead asset, COTI‑2—a novel oral small molecule targeting p53—was in Phase 1b/2a trials in combination with cisplatin across multiple solid tumors including ovarian and head & neck cancers. Early interim data showed no dose-limiting toxicities through two cohorts with broad enrollment across several difficult-to-treat cancers. The company’s second asset, COTI‑219—a selective inhibitor of mutant KRAS—was undergoing IND-enabling studies as of the latest public disclosures. Orphan drug designation was granted by the FDA to COTI‑2 for ovarian cancer treatment.[1][2][5][6]